1. Home
  2. ZYME vs CASH Comparison

ZYME vs CASH Comparison

Compare ZYME & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$22.88

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Pathward Financial Inc.

CASH

Pathward Financial Inc.

HOLD

Current Price

$91.17

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZYME
CASH
Founded
2003
1954
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
ZYME
CASH
Price
$22.88
$91.17
Analyst Decision
Strong Buy
Buy
Analyst Count
11
3
Target Price
$38.90
$96.33
AVG Volume (30 Days)
630.3K
228.1K
Earning Date
01-01-0001
04-23-2026
Dividend Yield
N/A
0.22%
EPS Growth
33.33
18.88
EPS
N/A
1.57
Revenue
$105,965,000.00
$839,894,000.00
Revenue This Year
$162.82
$7.56
Revenue Next Year
N/A
$6.02
P/E Ratio
N/A
$57.18
Revenue Growth
38.87
11.29
52 Week Low
$9.03
$64.45
52 Week High
$28.49
$96.06

Technical Indicators

Market Signals
Indicator
ZYME
CASH
Relative Strength Index (RSI) 43.81 53.25
Support Level $22.23 $71.74
Resistance Level $23.66 $95.58
Average True Range (ATR) 1.42 2.81
MACD -0.05 -0.74
Stochastic Oscillator 9.06 45.07

Price Performance

Historical Comparison
ZYME
CASH

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: